TR-O cells are primary cancer cells extracted from malignant human ovarian tumor tissue. Primary cells retain the properties of the original tumor, including the diversity of its many cancer cell populations, better than established cell-lines do; the latter lose several features of the original parental tumors during establishment and passage. This retention of donor variability and tissue complexity is important, given the trend towards personalised medicine. TR-O cells divide and multiply a finite number of times, unlike cell lines, which divide indefinitely, and are harder to grow. They therefore enable investigation of the originating donor, and not just of anonymous cells from cell lines, and are a valuable resource for the investigation of tumor biology.
Tissue is extracted from malignant human breast tumor tissue that is resected and removed during surgery and processed for primary culture. The TR-O platform consists of heterogenous primary cancer cells in the packaged units. The cells comprise both adherent and suspension populations (i.e. both anchorage dependent and independent cells). Each lot of TR-O originates from a single patient, and the cells are capable of forming spheroids and organoids in the appropriate culture conditions. These cells can be grafted in mice and are suitable for basic and applied (pre-clinical) research in patient derived xenografts modelling.
Care is taken to ensure the safety of the donor and the integrity of tumor tissue (discarded biosample), and all cell/tissue collection and handling procedures are compliant with government and Institutional Ethics Committee (IEC). Donors are tested for infection by HIV-1, HIV-2, HBV, HCV, Mycoplasma, Bacteria, Yeast and Fungi before collection. The product is ready-to-use and can be used without any additional cell culture procedures.
Disclaimer: Product for in vitro research use and xenografts models only. Not approved for diagnostic, therapeutic, or clinical applications.